Reshma Rangwala - 29 Feb 2024 Form 4 Insider Report for Karyopharm Therapeutics Inc. (KPTI)

Signature
/s/Nancy Smith as Attorney-in-Fact for Reshma Rangwala
Issuer symbol
KPTI
Transactions as of
29 Feb 2024
Net transactions value
-$25,493
Form type
4
Filing time
04 Mar 2024, 19:41:35 UTC
Previous filing
29 Feb 2024
Next filing
23 Apr 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KPTI Common Sale $18,330 -15,667 -4.2% $1.17 355,689 29 Feb 2024 Direct F1, F2
transaction KPTI Common Sale $7,163 -5,969 -1.7% $1.20 349,720 01 Mar 2024 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on April 4, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.
F2 Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $1.11 to $1.18, inclusive. The reporting person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3 This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on April 4, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of performance-based restricted stock units. The sale does not represent a discretionary trade by the reporting person.